NEPH vs NVCR

For growth investors, Nephros, Inc.

(NEPH) is the stronger pick with 32. 7% revenue growth year-over-year, versus 8. 3% for NovoCure Limited (NVCR). Nephros, Inc. (NEPH) offers the better valuation at 29. 4x trailing P/E, making it the more compelling value choice. Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Nephros, Inc.

(NEPH) delivered a total return of -56. 3%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: NVCR returned +30. 3% versus NEPH's +2. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Nephros, Inc.

(NEPH) is the lower-risk stock at 0. 59β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 272% more volatile than NEPH relative to the S&P 500. On balance sheet safety, Nephros, Inc. (NEPH) carries a lower debt/equity ratio of 10% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Nephros, Inc.

(NEPH) is pulling ahead at 32. 7% versus 8. 3% for NovoCure Limited (NVCR). Over a 3-year CAGR, NEPH leads at 23. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Nephros, Inc.

(NEPH) is the more profitable company, earning 6. 4% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 6. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NEPH leads at 6. 1% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Nephros, Inc.

(NEPH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 59)). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NEPH: +2. 5%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NEPH is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.